Medicines and Healthcare Products Regulatory Agency

Report No: ***UK MIA 17907 Insp GMP 17907/29140-0001 NCR***

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer [1]

Part 1

Issued following an inspection in accordance with :
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:
The manufacturer: ***BRISTOL LABORATORIES LIMITED***
Site address: ***UNIT 3, CANALSIDE, NORTHBRIDGE ROAD, BERKHAMSTED, HP4 1EG, United Kingdom***

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2017-07-17*** , it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC

[1] *The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and 80(7) of Directive 2001/82/EC, as amended, shall also be required for imports coming from third countries into a Member State.*

Part 2

Human Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS	
Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;	
1.2	**Non-sterile products**
	1.2.2 Batch certification

2 NON-COMPLIANT IMPORTATION OPERATIONS	
2.2	**Batch certification of imported medicinal products**
	2.2.2 Non-sterile products
2.3	**Other importation activities**
	2.3.1 Site of physical importation

Clarifying remarks (for public users)

The scope of this statement of non-compliance is limited to medicinal products considered non-critical to public health. Where manufacture and/or testing is continued for critical products, this should be supported by a documented risk assessment containing sufficient information to support activity on a risk management basis.

Part 3

1. Nature of non-compliance:
The inspections of the Bristol Laboratories Peterlee and Luton sites in April and July 2017 respectively, identified critical deficiencies that could also impact products imported, certified and released by the Berkhamsted site.

Action taken/proposed by the NCA

Withdrawal, of current valid GMP certificate No. UK MIA 17907 Insp GMP/GDP 17907/29140-0017
Withdrawal of previous GMP Certificate No: UK MIA 17907 Insp GMP/GDP 17907/29140-0017. Issue of a statement of non-compliance and restricted GMP certificate will be issued to permit continued manufacture and testing of products considered to be medically critical or to ensure continuity of supply, as determined by the national competent authority. Due to the nature of the issues identified batches of any non-critical products not released to market are included in the scope of this SNC.

Prohibition of supply
No batches of non-critical product to be supplied to EU markets whilst this statement of non-compliance remains in force.

Additional comments
National Competent Authorities should evaluate the criticality of products being supplied by this manufacturing site and enact measures to ensure continued supplies where appropriate. Marketing authorisation holders are requested to contact the relevant National Authority to verify whether their products are considered medically critical to public health in their territory and therefore outside the scope of this non-compliance statement.

2017-10-02

Name and signature of the authorised person of the Competent Authority of United Kingdom

---

Confidential
Medicines and Healthcare Products Regulatory Agency
Tel: ***Confidential***
Fax: ***Confidential***